UPCOMING WEBINARS

 

Tues 21st September 2021 @7pm

Understanding your NHS Pension and Benefits
Join Michael Copeland and Wilf Moralee
Sponsored by Wesleyan

 

Wed 22nd September 2021 @7pm

The latest breakthrough in 3M technology - 3M™ Scotchbond™ Universal Plus adhesive and 3M™ RelyX™ Universal resin cement
Dr John Rafelt
Sponsored by 3M

 

Thurs 30th September 2021 @7pm

The Power, Art, Synergy and Simplicity of Digital Dentistry
Dr Rob Chaffe and Steve Campbell
Sponsored by Align

 

Tues 5th October 2021 @7pm

A team approach to periodontal management – together we achieve more!
Helen Minnery
Sponsored by Waterpik

 

Article: Volume 48 Number 2 Page 127 - February 2021

  Dent Update 2021; 48: 127-132  Read article

Paediatric dentistry:  Is there a Role for Casein Phosphopeptide–Amorphous Calcium Phosphate (CPP-ACP) in Paediatric Dentistry?

CPD:  CPD  0:24   (closed)      Self assess

Feedback:  0 comments, 0 ratings

      

Abstract: In the age of minimally invasive dentistry, products with the ability to prevent and reverse common dental diseases are becoming increasingly popular. Casein phosphopeptide–amorphous calcium phosphate (CPP–ACP) contains the compounds casein, phosphate and calcium, which all have the ability to remineralize enamel. Dental caries, visible demineralization following removal of orthodontic appliances, non-carious tooth surface loss and dentine hypersensitivity due to structural anomalies are frequently seen in children and young people. The evidence for CPP–ACP and fluoride-containing CPP–ACP is positive for managing dental caries and non-carious tooth surface loss, specifically erosion, but is less clear in the management of visible demineralization following orthodontic appliance removal and dentine hypersensitivity owing to structural anomalies. When recommending CPP–ACP-containing products, dental practitioners should be aware of medical and social contra-indications that preclude its use.

Clinical relevance: CPP–ACP may have a role in the management of common paediatric dental conditions.

Author notes: Claire Warner BDS, MFDS RCPS(Glasg), PGCert MedEd, MClinDent, MPaedDent RCPS(Glasg), Specialist in Paediatric Dentistry, Community Dental Services CIC, Derbyshire, UK. Helen J Rogers BDS, MJDF RCS(Eng), PGDipConSed, MClinRes, MPaed Dent RCS(Eng), Clinical Lecturer in Paediatric Dentistry, School of Dental Sciences, Newcastle University, UK. email: claire.warner4@nhs.net

Objective: To describe the mechanism of action of casein phosphopeptide–amorphous calcium phosphate and the evidence base surrounding its use in common dental conditions experienced by children and young people.

NSK_July_2021
Denplan_Sept_Horizontal_2021